Experience

Oxford University Innovation

• United Kingdom
• Investment Management
• 1 - 100 Employee

• Deputy Head of Licensing & Ventures - Life Sciences

  • Mar 2022 - Oct 2023



Chemoinformatics Start-up at UCSF

• Business Development and Financing Consultant

  • Jun 2019 - Aug 2021

  San Francisco Bay Area Development of the business case for an AI driven fragment-based drug discovery (AI-FBDD) firm and recruitment of strategic investors with $2 million raised in 2019. Structured an EU based subsidiary to leverage projects from research institutes and biopharma companies. Company was acquired by a large AI focused therapeutics developer in 2021.



TissueGUARD

• Germany
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Business Development and Financing Consultant

  • Aug 2019 - Mar 2020

  Dresden, Germany Supported TissueGUARD GmbH in moving its innovative hydrogel products into the clinic and in closing a funding round. The company is developing breakthrough chemistry in degradable hydrogels and is currently partnered with world-leading clinicians in ophthalmology.



Computational Drug Discovery Team at TU-Dresden

• Business Development

  • Oct 2017 - Jul 2019

  Dresden, Germany Creation of a business case for a computational drug discovery engine; validation of the technology and license negotiations with industry; partnering with big Pharma and with venture investors.



Center for Regenerative Therapies Dresden

• Tech Transfer and IP Manager

  • Oct 2014 - Sep 2017

  Dresden, Germany Evaluation of IP, business proposals and collaborative opportunities, with hands-on support for patent filing, start-up and licensing, and partnering with industry.



Life Science Inkubator Sachsen

• Site Manager

  • May 2013 - Jul 2014

  Dresden, Germany Established all aspects of operations in Saxony and managed three transfer projects in stem cell science and photonics.



JADO Technologies GmbH

• CEO / CSO

  • 2000 - 2013

  Established JADO as a spin-out of the Max-Planck Institute of Molecular Cell Biology in Dresden to develop novel anti-inflammatory and anti-viral pharmaceuticals, targeting cell membrane rafts. JADO developed potent amphiphilic drug candidates for arthritis, urticaria, and mastocytosis. I served as CEO/CSO, raising 14 million Euro in Venture Capital from EU and US investors and led partnerships with EU and Japanese pharma companies.



HepaVec AG and DeveloGen AG (Germany)

• Director of Cell Engineering

  • 1995 - 2000